Ixazomib, pomalidomide and dexamethasone in triple-class exposed multiple myeloma patients - a phase II study
Tamir Shragai, Noa Lavi, Iuliana Vaxman, Moshe E. Gatt et autres
il (code pays fourni par la source)
0 citations
Haematologica
Noa Lowenton‐Spier
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
14Publications signalées
204Citations signalées
1Affiliations récentes
Les institutions déclarées
Les domaines associés
Multiple Myeloma Research and TreatmentsGlioma Diagnosis and TreatmentVirus-based gene therapy researchProtein Degradation and InhibitorsCancer Research and Treatments
Les publications récentes
Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test
Irit Avivi, Miriam Neaman, Noa Lowenton‐Spier, Chava Perry et autres
il, gr, lt, cz (code pays fourni par la source)
0 citations
Blood
Functional Geriatric Assessment Tests Predict Toxicity Rates in Functional High Risk Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone in a Prospective Clinical Trial
Ronit Shmuel, Rotem Tellem, Moshe E. Gatt, Noa Lavi et autres
il, us (code pays fourni par la source)
0 citations
Blood
A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib, Pomalidomide and Dexamethasone Combination As Second or Third-Line Treatment for Triple-Class Exposed Patients with Relapsed and Refractory Multiple Myeloma (iPod-790 Trial)
Yaël C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman et autres
il, us (code pays fourni par la source)
0 citations
Blood
A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)
Yaël C. Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman et autres
il (code pays fourni par la source)
1 citation
Blood
Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.
Yaël C. Cohen, Moshe E. Gatt, Efrat Luttwak, Noa Lavi et autres
il (code pays fourni par la source)
1 citation
Blood
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma
Irit Avivi, Roi Balaban, Tamir Shragai, Gabi Sheffer et autres
il (code pays fourni par la source)
77 citations
British Journal of Haematology
Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma
Benjamin M. Ellingson, Kunal Patel, Chencai Wang, Catalina Raymond et autres
us, il (code pays fourni par la source)
3 citations
Neuro-Oncology Advances
NIMG-17. VALIDATION OF DIFFUSION MRI AS AN IMAGING BIOMARKER FOR BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA IN A RANDOMIZED PHASE III TRIAL OF BEVACIZUMAB WITH OR WITHOUT VB-111 (GLOBE)
Benjamin M. Ellingson, Timothy F. Cloughesy, Chencai Wang, Kunal Patel et autres
us, il (code pays fourni par la source)
0 citations
Neuro-Oncology
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study
Andrew Brenner, Katherine B. Peters, James J. Vredenburgh, Felix Bokstein et autres
us, il (code pays fourni par la source)
39 citations
Neuro-Oncology
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
Timothy F. Cloughesy, Andrew Brenner, John de Groot, Nicholas Butowski et autres
us, il, ca (code pays fourni par la source)
75 citations
Neuro-Oncology
ATIM-19. RESULTS OF THE GLOBE STUDY: A PHASE 3, RANDOMIZED, CONTROLLED, DOUBLE-ARM, OPEN-LABEL, MULTI-CENTER STUDY OF VB-111 COMBINED WITH BEVACIZUMAB VS. BEVACIZUMAB MONOTHERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA
Timothy F. Cloughesy, Andrew Brenner, Nicholas Butowski, Yaël C. Cohen et autres
us, il (code pays fourni par la source)
6 citations
Neuro-Oncology
BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.